Toggle Nav
$2,980.00

KCL22-s/Cre stable cell line

Catalog number
CL-2112
Description
KCL22-s/Cre cells are derived from human lymphoblast-like cell line KCL22-s by stably integration of a constitutive Cre recombinase stably expression construct. KCL22-s cells are a variant of the KCL22 cell line that is sensitive to imatinib, a tyrosine kinase inhibitor commonly used to treat chronic myeloid leukemia (CML). Imatinib targets the BCR-ABL fusion protein, which is a key driver of CML. The paired KCL22-s and KCL22-r clones are useful cell line models of sensitivity and resistance to imatinib. KCL22-s/Cre cells stably express a nuclear localized Cre recombinase.
KCL22-s/Cre stable cell line
Product Details

Product Details

Package Size 2 x 10^6 cells
Parental cell line KCL22-s cells
Transgenic gene Cre recombinase
Mammalian selection Puromycin
Biosafety level 2
Storage Liquid nitrogen
Availability 3-4 weeks
Shipping condition dry ice

Premade Stable Cell Lines

  1. GFP-Firefly luciferase control cell lines
  2. RFP-Firefly luciferase control cell lines
  3. Fluorescent control cell lines
  4. Firefly luciferase control cell lines
  5. Signaling pathway reporter cell lines
  6. Cre stable cell lines
Copyright © 2024, FenicsBIO. All rights reserved.